LEPI Study:

Safety and Efficacy of the LVIS™ and LVIS™ Jr Devices in the Endovascular Treatment of Intracranial Aneurysms
LVIS™ Coil Assist Stent

"This study provides evidence that the LVIS™/LVIS™ Jr devices are safe and effective in the treatment of complex intracranial aneurysms, with very high rates of adequate occlusion at FU. These angiographic results are stable over time with an acceptable complication rate."

Patients

130

Country

France

Clinical Centers

17

Design

Single arm prospective

Scope

Patients with ruptured or unruptured aneurysms treated with LVIS™/LVIS™ Jr in France.

Purpose

Collect data on safety of the LVIS™/LVIS™ Jr devices used in a routine practice post reimbursement in France.

Endpoints

Cumulative morbidity and mortality rate (CMMR) assessed at 12-month follow-up, defined by the incidence of adverse events (AEs) with sequelae related to the treatment and/or device

Efficacy results

  • Treatment success: 100%

At 16.8 months:

  • Complete/nearly complete occlusion: 92.6%

  • Retreatment rate: 2.5%

Safety results

1 year:

  • Mobi-mortality related to the procedure and/or device: 4.6%

  • Overall mortality: 1.5%, none related to the procedure and/or device

LINK TO STUDY PAGE ClinicalTrials.gov ID NCT03553771


Please refer to Instruction for Use (IFU) in the specific market/country that you are looking into:

Explore more studies

HDE Study : Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support) Device

LVIS™ Coil Assist Stent

Pivotal study: Pivotal Study of the LVIS™ (Low Profile Visualized Intraluminal Support)

LVIS™ Coil Assist Stent

TRAIL Study: Treatment of Intracranial Aneurysms With LVIS™ System

LVIS™ Coil Assist Stent

Request more information

The information you provide through this form is necessary to respond to your request and may be shared with the relevant Terumo Neuro group entity or entities responsible for handling it. For more information on how we process your personal data and on your rights, please refer to our privacy policy.